[Clinical Characteristics and Risk Factors of Low Fibrinogenemia Induced by Hemocoagulase].

OBJECTIVE

To investigate the clinical characteristics and risk factors of low fibrinogenemia (LF) induced by hemocoagulase.

METHODS

Clinical data of 57 patients with hypofibrinogenemia (LF group) treated with hemocoagulase during Jan.2015 to Oct. 2018 in our hospittal were analyzed retrospectively. The control group consisted of 60 patients who did not develop hypofibrinogenemia treated with hemocoagulase. The clinical characteristics were compared between these two groups, the univariate analysis and multivariate analysis were also performed.

RESULTS

In LF group, the fibrinogenemia occurred on 5.4(σ=1.067) days after use of hemocoagulase，with the main manifestations as bleeding from the operation or wound site, the decrease of fibrinogen (0.694 g/L,σ=0.211), the increase of D-dimer (4.468μg/mL,σ=1.442) and the recovery of Fib on the day 3.93 (σ=0.563) after drug withdrawal. There were significant differences in age, sex, primary disease, origin of snake venom, course of treatment, complication of hepatic and renal insufficiency and route of administration between the 2 groups (P＜0.05). Multivariate logistic regression analysis showed that age(P=0.007,OR=11.248), course of treatment (P＜0.001,OR=72.104) and route of administration (P=0.049,OR=13.389) were risk factors for hypofibrinogenemia.

CONCLUSION

The use of hemocoagulase should be vigilant against the occurrence of hypofibrinogenemia. Old age, long course of treatment and the intravenous administration may increase the risk of hypofibrinogenemia.